MX2009011416A - Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. - Google Patents

Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Info

Publication number
MX2009011416A
MX2009011416A MX2009011416A MX2009011416A MX2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A MX 2009011416 A MX2009011416 A MX 2009011416A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
zoles
thia
dia
compounds
Prior art date
Application number
MX2009011416A
Other languages
English (en)
Inventor
Gregor James Macdonald
Jose Manuel Bartolome-Nebreda
Michiel Luc Maria Van Gool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009011416A publication Critical patent/MX2009011416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a [1-(bencil)-piperidin-4-iI]-([1 ,3,4]tiadiazol-2-iI)-amina y derivados de [1-(bencil)-piperidin-4- il]-(tiazol-2-il)-amina de fórmula (I) que son antagonistas del receptor de dopamina 2 de disociación rápida, los procesos para preparar estos compuestos, las composiciones farmacéuticas que comprenden estos compuestos como un ingrediente activo; los compuestos se usan como medicamentos para tratar o prevenir trastornos del sistema nervioso central, por ejemplo esquizofrenia, al ejercer un efecto antipsicótico sin efectos secundarios motores.
MX2009011416A 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. MX2009011416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106706 2007-04-23
PCT/EP2008/054732 WO2008128996A1 (en) 2007-04-23 2008-04-18 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009011416A true MX2009011416A (es) 2009-11-05

Family

ID=38476031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011416A MX2009011416A (es) 2007-04-23 2008-04-18 Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.

Country Status (15)

Country Link
US (1) US8933101B2 (es)
EP (1) EP2148879B1 (es)
JP (1) JP5431306B2 (es)
KR (1) KR101506156B1 (es)
CN (1) CN101663299A (es)
AR (1) AR066242A1 (es)
AU (1) AU2008240729B2 (es)
CA (1) CA2682671C (es)
CL (1) CL2008001158A1 (es)
ES (1) ES2400710T3 (es)
IL (1) IL201661A (es)
MX (1) MX2009011416A (es)
RU (1) RU2489431C2 (es)
TW (1) TWI423969B (es)
WO (1) WO2008128996A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
SI2148873T1 (sl) * 2007-04-23 2013-01-31 Janssen Pharmaceutica, N.V. Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
CA2730774C (en) * 2008-07-31 2016-09-13 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) * 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
CA2176722A1 (en) 1993-12-28 1995-07-06 Ruth E. Ten Brink Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
IL133960A0 (en) 1997-08-15 2001-04-30 Pfizer Prod Inc 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
NZ527365A (en) 2001-02-23 2005-08-26 Merck & Co Inc N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
KR100938369B1 (ko) 2001-10-09 2010-01-22 교린 세이야꾸 가부시키 가이샤 신규 4-(2-푸로일)아미노피페리딘, 그의 합성 중간체,그의 제조방법 및 의약으로서의 그의 용도
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
IL162859A0 (en) 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
MXPA04008097A (es) 2002-02-22 2004-11-26 Upjohn Co Derivados de piridilsulfona como antagonistas del receptor 5-ht.
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
EP1543830B1 (en) * 2002-09-26 2012-03-28 Mandom Corporation Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
ATE476954T1 (de) 2003-05-07 2010-08-15 Kemira Pigments Oy Zusammensetzungen zur gezielten freisetzung von duftstoffen und aromen
CA2524498C (en) 2003-05-08 2012-01-24 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching
DK1648882T3 (da) * 2003-06-04 2008-11-24 Merck & Co Inc 3-fluor-piperidiner som NMDA/NR2B-antagonister
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
ES2342605T3 (es) 2003-07-29 2010-07-09 High Point Pharmaceuticals, Llc Piridazinil-piperazinas y su uso como ligandos del receptor histaminico h3.
EP3042895A1 (en) 2003-07-30 2016-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
JP2007501801A (ja) 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
MXPA06009099A (es) 2004-02-10 2007-02-02 Johnson & Johnson Piridazinona ureas como antagonistas de las integrinas alfa-4.
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2005105779A1 (en) 2004-04-28 2005-11-10 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
EP1753429A1 (en) 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
AR052319A1 (es) 2004-10-29 2007-03-14 Kalypsys Inc Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar
AU2005313391A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
CA2602654A1 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
MX2008000115A (es) 2005-06-20 2008-03-18 Schering Corp Derivados de piperidina utiles como antagonistas de histamina h3.
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
CN101506165B (zh) 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
SI2148873T1 (sl) * 2007-04-23 2013-01-31 Janssen Pharmaceutica, N.V. Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
PE20091194A1 (es) * 2007-09-20 2009-09-05 Glaxo Group Ltd Derivados de heterociclicos como moduladores del receptor m1
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
CA2730774C (en) 2008-07-31 2016-09-13 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists

Also Published As

Publication number Publication date
AU2008240729A1 (en) 2008-10-30
CN101663299A (zh) 2010-03-03
US20100120860A1 (en) 2010-05-13
WO2008128996A1 (en) 2008-10-30
JP5431306B2 (ja) 2014-03-05
EP2148879A1 (en) 2010-02-03
CA2682671C (en) 2015-11-17
ES2400710T3 (es) 2013-04-11
KR20100016090A (ko) 2010-02-12
JP2010525015A (ja) 2010-07-22
CA2682671A1 (en) 2008-10-30
IL201661A0 (en) 2010-05-31
RU2009142981A (ru) 2011-05-27
TWI423969B (zh) 2014-01-21
RU2489431C2 (ru) 2013-08-10
AR066242A1 (es) 2009-08-05
EP2148879B1 (en) 2012-11-28
TW200911799A (en) 2009-03-16
AU2008240729B2 (en) 2012-08-23
KR101506156B1 (ko) 2015-03-26
CL2008001158A1 (es) 2008-11-03
US8933101B2 (en) 2015-01-13
IL201661A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
HK1124317A1 (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
JO2849B1 (en) Dopamine 2 receptor antagonists are rapidly hydrolyzed
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
MX2009011415A (es) Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
MX2009011416A (es) Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
MY148772A (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
MY137272A (en) Imidazole derivatives
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
MX2009011414A (es) Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida.
MXPA05013233A (es) Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
MY142085A (en) Imidazole derivatives

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration